Drug Trial Radar · NCT07588100
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 18, 2026
Primary completion
Jan 20, 2028
Study completion Jan 20, 2028
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety, tolerability, and pharmacokinetics (PK) of intravitreal (IVT) injections of RO7663498 in participants with diabetic retinopathy (DR).
Conditions
- Diabetic Retinopathy
Interventions
RO7663498Drug
Participants will receive RO7663498 as per the schedule defined in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Ocular Adverse Events (AEs)Time frame: Up to Week 20
- Percentage of Participants With Systemic (non-ocular) AEsTime frame: Up to Week 20
- Number of Abnormalities Recorded in Standard Ophthalmological AssessmentsTime frame: Up to Week 20
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Global Research Management
Glendale, California · Recruiting
University Retina and Macula Associates, PC
Oak Forest, Illinois · Recruiting
Ohio State Havener Eye Institute;Ophthalmology Research
Columbus, Ohio · Recruiting
Medical Center Ophthalmology Associates
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.